Glenmark Gets USFDA Approval for Fluticasone Nasal Spray

Glenmark Pharmaceuticals Limited received approval from the U.S. Food and Drug Administration for Fluticasone Propionate Nasal Spray USP, 0.05 mg (50 mcg) per spray. The product is a generic version of Flonase Nasal Spray, 0.05 mg per spray, which is marketed by Haleon US Holdings LLC in the United States.

Fluticasone Propionate Nasal Spray

Fluticasone propionate is a corticosteroid used in nasal spray formulations for allergic rhinitis and related nasal symptoms. The approved Glenmark product is bioequivalent and therapeutically equivalent to the reference listed drug, which is a standard regulatory requirement for generic medicines in the United States.

USFDA Approval and Generic Drug Standards

The U.S. Food and Drug Administration regulates prescription and over-the-counter medicines in the United States. A generic drug must match the reference listed drug in dosage form, strength, route of administration, quality, performance characteristics, and intended use.

Glenmark stated that Glenmark Pharmaceuticals Inc., USA will distribute the product across the United States market. The company also cited IQVIA sales data showing that Flonase Nasal Spray recorded annual sales of about $295.2 million for the 12-month period ending June 2026.

Glenmark’s Respiratory Portfolio

Marc Kikuchi is the President and Business Head of North America for Glenmark. He stated that the approval adds to the company’s respiratory portfolio in the United States.

On March 4, 2026, Glenmark Specialty SA received final U.S. FDA approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation. That product is a generic equivalent of GSK’s Flovent HFA.

Important Facts for Exams

• The U.S. Food and Drug Administration is the federal agency that regulates medicines, food, medical devices, and vaccines in the United States.
• Bioequivalence means that a generic drug releases the same active ingredient into the bloodstream at a similar rate and extent as the reference drug.
• Therapeutic equivalence is used in the United States for drugs that are expected to have the same clinical effect and safety profile as the reference product.
• Fluticasone propionate belongs to the corticosteroid class of medicines and is used in nasal and inhalation formulations.